Allogene Therapeutics ALLO Business Segments — All other development costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept allo:ResearchAndDevelopmentExpenseOtherDevelopmentCosts.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's business segments — all other development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's business segments — all other development costs?
- Allogene Therapeutics (ALLO) reported business segments — all other development costs of $2M in Q1 2026.
- How has Allogene Therapeutics's business segments — all other development costs changed year-over-year?
- Allogene Therapeutics's business segments — all other development costs decreased by 80.8% year-over-year, from $10.39M to $2M.
- What is the long-term trend for Allogene Therapeutics's business segments — all other development costs?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — all other development costs has grown at a -8.8% compound annual growth rate (CAGR), from $24.46M to $20.34M.
- What does business segments — all other development costs mean?
- This metric captures the aggregate research and development spending for the company's pipeline assets excluding the lead program. It reflects the breadth of the company's early-stage innovation efforts and diversification of its clinical portfolio. Tracking this allows for an evaluation of the company's broader R&D strategy beyond its primary asset.